Abstract 2105
Background
Extracellular matrix (ECM) is a basic step of tumor invasion and metastasis. Matrix metalloproteinase (MMPs) family is a kind of zinc-ion-dependent endopeptidase, which can degrade almost all protein components in the extracellular matrix, destroy the histological barrier of tumor cell invasion, and play a key role in tumor invasion and metastasis. The role of MMP-9 in tumor invasion and metastasis has attracted increasing attention and is considered as the main proteolytic enzyme in this process. The aim of this study was to investigate the role of MMP-9 in human oral squamous cell carcinoma cells.
Methods
Human oral squamous cell carcinoma (OSCC) cells CAL27 and SCC-15 were cultured in DMEM high glucose medium with 10% FBS. The MMP-9-shRNA Lentiviral clone and control virus was constructed and transfected into OSCC cells. Cell proliferation was detected by MTT assay. Colony formation was evaluated by colony formation assay. Cell migration and invasion was evaluated using the scratch assay and transwell invasion assay. OSCC cells Knockdown with MMP-9-shRNA were injected into zebra fish and OSCC tumor model in zebra fish was established and evaluated.
Results
MMP-9 expression was down regulated significantly in RNA and protein level after transfection. Knockdown of MMP-9 gene by shRNA could inhibit oral squamous cell cancer cells growth and colony formation, and markedly suppress cell migration and invasion in vitro. And also knockdown of MMP-9 gene could significantly inhibit OSCC cells metastasis in zebra fish.
Conclusions
MMP-9 plays an important role in OSCC cells metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beijing Stomatological Hospital & School of Stomatology, Capital Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1851 - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients
Presenter: Nobuaki Mamesaya
Session: Poster Display session 1
Resources:
Abstract
851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)
Presenter: Cristina Lopez Escola
Session: Poster Display session 1
Resources:
Abstract
3639 - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 1
Resources:
Abstract
2950 - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer
Presenter: Haixi Yan
Session: Poster Display session 1
Resources:
Abstract
3659 - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.
Presenter: Joori Kim
Session: Poster Display session 1
Resources:
Abstract
4882 - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment
Presenter: Florian Guisier
Session: Poster Display session 1
Resources:
Abstract
1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study
Presenter: Hayato Kawachi
Session: Poster Display session 1
Resources:
Abstract
3051 - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab
Presenter: Yuki Sato
Session: Poster Display session 1
Resources:
Abstract
3409 - Effect and safety of immune checkpoint inhibitors for brain metastases from non-small cell lung cancer
Presenter: Toshihiko Iuchi
Session: Poster Display session 1
Resources:
Abstract